GlassScriptPhysician profile
Clare Ann Roewe
NPI 1083221717
$1,272.78
in general payments reported to CMS, 2019-2025
17 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $447 · 2023: $195 · 2024: $98.60 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $227.44 | 2021-2025 | Saphnelo, Fasenra |
| Novo Nordisk INC | $123.11 | 2021 | |
| Biogen, INC. | $119.68 | 2023 | Tysabri |
| Bayer Healthcare Pharmaceuticals INC. | $119.20 | 2022 | |
| Abbvie INC. | $114.36 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $113.34 | 2021 | |
| Glaxosmithkline, LLC. | $112.89 | 2022 | |
| Boston Scientific Corporation | $112.39 | 2022 | |
| Grifols USA, LLC | $57.73 | 2022-2025 | Prolastin-C Liquid |
| Organon LLC | $41.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.95 | 2023 | Elaprase |
| Lundbeck LLC | $21.33 | 2024 | Vyepti |
| Octapharma USA, INC. | $20.80 | 2024 | Octagam Immune Globulin (Human) |
| Chiesi USA, INC. | $20.15 | 2024 | Elfabrio |
| Genzyme Corporation | $19.83 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $14.48 | 2025 | |
| Janssen Biotech, INC. | $12.72 | 2023 | Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clare Roewe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.